Formulary
Telotristat ethyl: Indications, Dosing, Side Effects and Interactions
Telotristat ethyl and its active metabolite inhibit L-tryptophan hydroxylases TPH-1 and TPH-2 which reduces the production of serotonin, thereby alleviating...
MedNext Academy | 3 min read
Telotristat ethyl: Indications, Dosing, Side Effects and Interactions
Telotristat ethyl and its active metabolite inhibit L-tryptophan hydroxylases TPH-1 and TPH-2 which reduces the production of serotonin, thereby alleviating...
Drug action
Telotristat ethyl and its active metabolite inhibit L-tryptophan hydroxylases TPH-1 and TPH-2 which reduces the production of serotonin, thereby alleviating symptoms associated with carcinoid syndrome.
Indications and dose
**Carcinoid syndrome diarrhoea (specialist use only)**
- **Adult** (By Mouth): 250 mg 3 times a day, review treatment if no response after 12 weeks.
Side effects
Common or very common Appetite decreased; depression; fatigue; fever; gastrointestinal discomfort; gastrointestinal disorders; headache; nausea; peripheral oedema
Interactions
**Severe interactions:**
- Effect of other medicinal products on Xermelo Short acting octreotide Concomitant administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat...
**Other interactions (4):**
- Short- acting octreotide should be administered at least 30 minutes after administration of Xermelo if treatment with short-acting octreotide is needed in combination with Xermelo.
- Concomitant use of Xermelo may decrease the efficacy of medicinal products that are CYP2B6 substrates (e.g.
- CYP3A4 substrates Concomitant use of Xermelo may decrease the efficacy of medicinal products that are CYP3A4 substrates (e.g.
- Carboxylesterase 2 (CES2) substrates Concomitant use of Xermelo may change the exposure of medicinal products that are CES2 substrates (e.g.
Pregnancy
Manufacturer advises avoid-toxicity in animal studies.
Breast feeding
Manufacturer advises avoid-no information available.
Hepatic impairment
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment (no information available). Dose adjustments Manufacturer advises consider dose reduction to 250 mg twice daily in mild impairment and to 250 mg once daily in moderate impairment, according to tolerability.
Renal impairment
Manufacturer advises caution in mild-to-moderate impairment; avoid in severe impairment-no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Telotristat ethyl in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

